InvestorsHub Logo
Followers 12
Posts 265
Boards Moderated 0
Alias Born 04/16/2020

Re: None

Monday, 03/08/2021 10:26:50 PM

Monday, March 08, 2021 10:26:50 PM

Post# of 426493
Good Evening Everyone,

We received what I consider another hope for Amarin and our investment. I pick and choose when to post over the past couple of years but after the UHC announcement today I wanted to share my 2 cents and experience in the pharma industry.

Taking into account everytime we received something positive on Amarin and our investment we then receive something negative. In my opinion this is by far the best news Amarin has received over the past couple of years other than the CVD Risk Reduction Indication.

Please do not view the Prior Approval (PA) that UHC placed on Vascepa as a negative or roadblock for any doctor that wants their patient that meets the criteria to receive Vascepa. This is exactly what we've all been asking fr and wanting. Just give us all of the CVD Risk Indication business with little to no threat of a Generic Vascepa being filled and we are good to go. This will happen for UHC patients that meet the CVD Risk Indication for Vascepa. We all know that the large majority of patientd for our drug.

Also those that are concerned that when a patient's trigs might go below 150 will they approve a patient to stay on Vascepa and the answer is a Resounding Yes. They won't take them off of a drug that has improved their condition and still has risk factors after meeting the criteria to be on the drug.

I've dealt with these types of situations my entire 30 year career in Pharma. What was announced today by UHC should only be viewed as very positive. UHC is a trendsetter and many other MC Plans will follow as the word gets out.

Wha we need now is the CAFC to uphold their ruling in favor of GSK and this battle is just about over and justice has been served for the Amarin Corporation and all of us.

It's been a long road but for the first time I see a bright light shining for Amarin, the Science and all of us.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News